Adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐ short term · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Adverse events: General: Severe adverse event ‐ any dose risperidone depot ‐ short term · patients with schizophrenia
1 finding from 1 review
Serious adverse events (5 mg/10 mg) · Patients with quiescent ulcerative colitis
Tofacitinib showed no clear difference in serious adverse events (5 mg/10 mg) compared with placebo (low certainty).
1 finding from 1 review
Adverse events (soft tissue trauma) · Individuals of any age with no reported disability that might affect toothbrushing (including people wearing orthodontic appliances)
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: thromboembolic events · Human trial participants undergoing ablation for atrial fibrillation
It is very uncertain whether class I and/or III antiarrhythmics changes adverse events: thromboembolic events compared with control (very low certainty).
1 finding from 1 review
Adverse events: myocardial infarction · Human trial participants undergoing ablation for atrial fibrillation
1 finding from 1 review
no estimate extracted
3 participants
GRADE not reported
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events and periodontal/secondary outcomes (gingival bleeding, gingival bleeding index, visible plaque index) · Children and adults with non-cavitated proximal (interproximal) caries lesions in primary and/or permanent teeth (ages 3-45)
Only three trials reported secondary/adverse outcomes; no adverse events were attributed to microinvasive treatment and periodontal findings were mixed and not pooled (ungraded).
1 finding from 1 review
Microinvasive interventions in the management of proximal caries lesions in primary and permanent teeth- systematic… 2025 All outcomesBaseline and follow-up · Multiple countries (Brazil, Saudi Arabia, Netherlands, USA, Turkey, Switzerland, Germany, New Zealand, Chile, Thailand); dental clinic/community settings
Reported narratively by 3 trials (Arthur 2018, Sarti 2020, Jorge 2019). No adverse events were attributed to microinvasive treatment. Gingival bleeding index: no significant difference in Arthur 2018 and Jorge 2019 but…
3 studies
GRADE not reported
Intervention not reported
Adverse events report of adverse events · patients with treating strongyloides infection
The intervention showed no clear difference in adverse events report of adverse events (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events report of adverse events · patients with treating strongyloides infection
The intervention probably leads to lower adverse events report of adverse events (moderate certainty).
1 finding from 1 review
Adverse events associated with treatment · Adults with oropharyngeal cancer
1 finding from 1 review
Adverse events: grade 2+ treatment-related events similar (31/34 radiotherapy vs 33/34 surgery; RR 0.94, 0.83 to 1.06); more hearing loss/neutropenia/constipation/tinnitus with radiotherapy, more oral bleeding/trismus…
1 study · 68 participants
Very low
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found